A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study
designed to evaluate the safety, PK, and exploratory activity of topically-applied NS2
dermatologic cream administered once-daily (QD) to subjects with ichthyosis secondary to
Sjögren- Larsson Syndrome (SLS).
NS2 is expected to trap fatty aldehydes that are pathogenic in SLS patients, and thereby
diminish the lipid-aldehyde adduct formation that likely results in ichthyosis associated
with SLS, and potentially reduce the mild dermal inflammation characteristic of SLS.